Reaxa CEO Dr Peter Jackson explains why the firm added a nickel catalyst to its EnCat range.
Reaxa showcases Ni EnCat technology
By Phil Taylor
Last updated on
Reaxa CEO Dr Peter Jackson explains why the firm added a nickel catalyst to its EnCat range.
Related Topics
Related news
Reaxa spin-off ADC Biotechnology talks new processing tech
A developmental purification system for Antibody-Drug-Conjugates will be launched by ADC Biotechnology (ADBC), a spin off from Reaxa, which promises reduced manufacturing costs for “magic bullet” cancer drugs.
Reaxa to lead $1m CP-STAR catalyst project
Reaxa has received a UK Technology Strategy Board (TSB) award to further development of cleaner catalysts for pharmaceutical manufacturing.
Reaxa gets UK grant for Ni EnCat scale-up
UK process technologies firm Reaxa has received a £146K (€164K) R&D grant from the Northwest Regional Development Agency (NWDA) to scale-up production of its EnCat nickel catalyst.